288 related articles for article (PubMed ID: 30249403)
1. MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy.
Mohajeri M; Banach M; Atkin SL; Butler AE; Ruscica M; Watts GF; Sahebkar A
Trends Pharmacol Sci; 2018 Nov; 39(11):967-981. PubMed ID: 30249403
[TBL] [Abstract][Full Text] [Related]
2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
3. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
Taylor BA; Thompson PD
Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
[TBL] [Abstract][Full Text] [Related]
4. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
5. Statin therapy-evidence beyond lipid lowering contributing to plaque stability.
de Lorenzo F; Feher M; Martin J; Collot-Teixeira S; Dotsenko O; McGregor JL
Curr Med Chem; 2006; 13(28):3385-93. PubMed ID: 17168712
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
[TBL] [Abstract][Full Text] [Related]
7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
8. Statin therapy in cardiovascular diseases other than atherosclerosis.
Beaudry D; Stone KE; Wetherold S; Hemphill J; Do D; McClish J; Chilton R
Curr Atheroscler Rep; 2007 Jan; 9(1):25-32. PubMed ID: 17228487
[TBL] [Abstract][Full Text] [Related]
9. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association.
Cohen JD; Cziraky MJ; Jacobson TA; Maki KC; Karalis DG
J Clin Lipidol; 2017; 11(4):891-900. PubMed ID: 28550993
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
11. Effect of statins on toll-like receptors: a new insight to pleiotropic effects.
Bahrami A; Parsamanesh N; Atkin SL; Banach M; Sahebkar A
Pharmacol Res; 2018 Sep; 135():230-238. PubMed ID: 30120976
[TBL] [Abstract][Full Text] [Related]
12. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
Sadowitz B; Maier KG; Gahtan V
Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.
King P; Nicholls SJ
Curr Cardiol Rep; 2017 Aug; 19(8):66. PubMed ID: 28643240
[TBL] [Abstract][Full Text] [Related]
14. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
15. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy.
Zhou Q; Liao JK
Curr Pharm Des; 2009; 15(5):467-78. PubMed ID: 19199975
[TBL] [Abstract][Full Text] [Related]
16. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of statins.
Liao JK; Laufs U
Annu Rev Pharmacol Toxicol; 2005; 45():89-118. PubMed ID: 15822172
[TBL] [Abstract][Full Text] [Related]
18. Effects of statin therapy on the progression of chronic kidney disease.
Shah S; Paparello J; Danesh FR
Adv Chronic Kidney Dis; 2005 Apr; 12(2):187-95. PubMed ID: 15822054
[TBL] [Abstract][Full Text] [Related]
19. Plaque regression and improved clinical outcomes following statin treatment in atherosclerosis.
Girotra S; Murarka S; Migrino RQ
Panminerva Med; 2012 Jun; 54(2):71-81. PubMed ID: 22525562
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of human HMG-CoA reductase in Saccharomyces cerevisiae: a system to analyse normal and mutated versions of the enzyme in the context of statin treatment.
Wysocka-Kapcinska M; Lutyk-Nadolska J; Kiliszek M; Plochocka D; Maciag M; Leszczynska A; Rytka J; Burzynska B
J Appl Microbiol; 2009 Mar; 106(3):895-902. PubMed ID: 19187128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
